{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:39:46Z","timestamp":1787060386727,"version":"build-2736575974"},"reference-count":10,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":373,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Cell"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ccell.2024.11.001","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T10:46:17Z","timestamp":1733741177000},"page":"1993-1996","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Molecular subtyping in urothelial carcinoma treatment"],"prefix":"10.1016","volume":"42","author":[{"given":"Xiaowen","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinan","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccell.2024.11.001_bib1","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.eururo.2023.05.011","article-title":"Checkpoint Inhibitors in Urothelial Carcinoma-Future Directions and Biomarker Selection","volume":"84","author":"Meeks","year":"2023","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ccell.2024.11.001_bib2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41571-023-00826-2","article-title":"Progress in systemic therapy for advanced-stage urothelial carcinoma","volume":"21","author":"Nadal","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ccell.2024.11.001_bib3","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1016\/j.ccell.2024.10.016","article-title":"Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade","volume":"42","author":"Hamidi","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2024.11.001_bib4","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2024.11.001_bib5","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/path.4886","article-title":"Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification","volume":"242","author":"Sj\u00f6dahl","year":"2017","journal-title":"J. Pathol."},{"key":"10.1016\/j.ccell.2024.11.001_bib6","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1200\/JCO.1999.17.10.3173","article-title":"Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy","volume":"17","author":"Bajorin","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2024.11.001_bib7","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.eururo.2012.11.042","article-title":"Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials","volume":"63","author":"Sonpavde","year":"2013","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ccell.2024.11.001_bib8","doi-asserted-by":"crossref","first-page":"S1145","DOI":"10.1016\/j.annonc.2024.08.2064","article-title":"1979P Disitamab vedotin (DV) plus toripalimab (T) in unresectable locally advanced or metastatic urothelial carcinoma (la\/mUC): Long-term outcomes from a phase Ib\/II study","volume":"35","author":"Zhou","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ccell.2024.11.001_bib9","doi-asserted-by":"crossref","first-page":"S1138","DOI":"10.1016\/j.annonc.2024.08.2052","article-title":"1967MO Preliminary efficacy and safety of disitamab vedotin (DV) with pembrolizumab (P) in treatment (Tx)-naive\u00a0HER2-expressing, locally advanced or metastatic urothelial carcinoma (la\/mUC): RC48G001 cohort C","volume":"35","author":"Galsky","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ccell.2024.11.001_bib10","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1200\/JCO.22.02912","article-title":"Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials","volume":"42","author":"Sheng","year":"2024","journal-title":"J. Clin. Oncol."}],"container-title":["Cancer Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610824004367?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610824004367?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T01:26:08Z","timestamp":1765243568000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535610824004367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":10,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1535610824004367"],"URL":"https:\/\/doi.org\/10.1016\/j.ccell.2024.11.001","relation":{},"ISSN":["1535-6108"],"issn-type":[{"value":"1535-6108","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular subtyping in urothelial carcinoma treatment","name":"articletitle","label":"Article Title"},{"value":"Cancer Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccell.2024.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ccell.2024.10.016","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}